Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry
VolitionRx (NYSE: VNRX) has announced promising results from a study of its automated Nu.Q® Cancer immunoassay test, demonstrating the test's ability to detect 21 different types of cancer. The test, which features a low false positive rate among healthy individuals, can be utilized either as a standalone pan-cancer screening tool or in combination with other liquid biopsy technologies to enhance accuracy.
The company is actively pursuing licensing agreements with major diagnostic and liquid biopsy companies, targeting multiple partnerships with milestone payments and ongoing revenue streams in 2025. A key advantage of Volition's nucleosome assays is their compatibility with existing automated chemiluminescence platforms worldwide, eliminating the need for new hardware investment. The technology targets the $20 billion Total Annual Accessible Market for liquid biopsy multi-cancer early detection in the U.S.
VolitionRx (NYSE: VNRX) ha annunciato risultati promettenti da uno studio sul suo test immunologico automatizzato Nu.Q® Cancer, dimostrando la capacità del test di rilevare 21 diversi tipi di cancro. Il test, che presenta un basso tasso di falsi positivi tra gli individui sani, può essere utilizzato sia come strumento di screening pan-cancer indipendente che in combinazione con altre tecnologie di biopsia liquida per migliorare l'accuratezza.
L'azienda sta attivamente perseguendo accordi di licenza con importanti aziende di diagnostica e biopsia liquida, puntando a molteplici partnership con pagamenti a tappe e flussi di entrate continuativi nel 2025. Un vantaggio chiave degli assay di nucleosoma di Volition è la loro compatibilità con le piattaforme di chemiluminescenza automatizzate esistenti in tutto il mondo, eliminando la necessità di investimenti in nuove attrezzature. La tecnologia mira al mercato totale annuale accessibile di 20 miliardi di dollari per la rilevazione precoce di più tumori mediante biopsia liquida negli Stati Uniti.
VolitionRx (NYSE: VNRX) ha anunciado resultados prometedores de un estudio sobre su prueba inmunoensayo automatizada Nu.Q® Cancer, demostrando la capacidad de la prueba para detectar 21 tipos diferentes de cáncer. La prueba, que presenta una baja tasa de falsos positivos entre individuos sanos, puede ser utilizada tanto como una herramienta de detección pan-cáncer independiente como en combinación con otras tecnologías de biopsia líquida para mejorar la precisión.
La empresa está persiguiendo activamente acuerdos de licencia con importantes empresas de diagnóstico y biopsia líquida, apuntando a múltiples asociaciones con pagos por hitos y flujos de ingresos continuos en 2025. Una ventaja clave de los ensayos de nucleosomas de Volition es su compatibilidad con las plataformas automatizadas de quimioluminiscencia existentes en todo el mundo, eliminando la necesidad de inversión en nuevo hardware. La tecnología apunta al mercado total anual accesible de 20 mil millones de dólares para la detección temprana de múltiples cánceres mediante biopsia líquida en EE. UU.
VolitionRx (NYSE: VNRX)는 자동화된 Nu.Q® 암 면역 분석 테스트에 대한 연구에서 유망한 결과를 발표하며, 이 테스트가 21가지 다른 유형의 암을 감지할 수 있는 능력을 보여주었습니다. 이 테스트는 건강한 개인 사이에서 낮은 위양성률을 특징으로 하며, 독립적인 범암 스크리닝 도구로 사용되거나 다른 액체 생검 기술과 결합하여 정확성을 높일 수 있습니다.
회사는 주요 진단 및 액체 생검 회사와의 라이센스 계약을 적극적으로 추진하고 있으며, 2025년까지 이정표 지급 및 지속적인 수익 흐름을 목표로 여러 파트너십을 추구하고 있습니다. Volition의 뉴클레오솜 분석의 주요 장점은 전 세계의 기존 자동화 화학 발광 플랫폼과의 호환성으로, 새로운 하드웨어 투자 필요성을 없애줍니다. 이 기술은 미국에서 액체 생검 다중 암 조기 탐지를 위한 200억 달러의 연간 총 접근 가능 시장을 목표로 하고 있습니다.
VolitionRx (NYSE: VNRX) a annoncé des résultats prometteurs d'une étude sur son test d'immunoessai automatisé Nu.Q® Cancer, démontrant la capacité du test à détecter 21 types différents de cancer. Le test, qui présente un faible taux de faux positifs parmi les individus en bonne santé, peut être utilisé soit comme un outil de dépistage pan-cancer autonome, soit en combinaison avec d'autres technologies de biopsie liquide pour améliorer la précision.
L'entreprise poursuit activement des accords de licence avec de grandes entreprises de diagnostic et de biopsie liquide, visant plusieurs partenariats avec des paiements d'étape et des flux de revenus continus en 2025. Un avantage clé des essais de nucléosomes de Volition est leur compatibilité avec les plateformes de chimiluminescence automatisées existantes dans le monde entier, éliminant ainsi la nécessité d'investissements dans de nouveaux matériels. La technologie vise le marché total annuel accessible de 20 milliards de dollars pour la détection précoce de plusieurs cancers par biopsie liquide aux États-Unis.
VolitionRx (NYSE: VNRX) hat vielversprechende Ergebnisse aus einer Studie zu seinem automatisierten Nu.Q® Krebs-Immunoassay-Test bekannt gegeben, der die Fähigkeit des Tests zur Erkennung von 21 verschiedenen Krebsarten demonstriert. Der Test, der eine niedrige falsch-positive Rate bei gesunden Personen aufweist, kann entweder als eigenständiges Pan-Krebs-Screening-Tool oder in Kombination mit anderen Flüssigbiopsie-Technologien zur Verbesserung der Genauigkeit eingesetzt werden.
Das Unternehmen verfolgt aktiv Lizenzvereinbarungen mit großen Diagnostik- und Flüssigbiopsie-Unternehmen und strebt mehrere Partnerschaften mit Meilensteinzahlungen und laufenden Einnahmequellen im Jahr 2025 an. Ein wesentlicher Vorteil von Volitions Nukleosomen-Assays ist ihre Kompatibilität mit bestehenden automatisierten Chemilumineszenz-Plattformen weltweit, wodurch die Notwendigkeit neuer Hardware-Investitionen entfällt. Die Technologie zielt auf den 20 Milliarden Dollar umfassenden jährlichen erreichbaren Markt für die frühzeitige Erkennung von mehreren Krebsarten durch Flüssigbiopsie in den USA ab.
- Test successfully detects 21 different cancer types
- Low false positive rate in healthy individuals
- Compatible with existing automated platforms, reducing implementation costs
- $20B total addressable market in U.S.
- Multiple licensing agreements with milestone payments expected in 2025
- Test still in development phase
- No licensing agreements finalized yet
Volition study shows rapid, low-cost, automated Nu.Q® Cancer test accurately detects human cancers at high specificity
Gael Forterre, Chief Commercial Officer at Volition, commented:
"Our mission since the company was incorporated was to help detect cancer early, with the aim of saving lives and improving outcomes.
"We are excited to publish this further validation of our Nu.Q® platform; it represents a potential opportunity to disrupt the
"We are in active discussions regarding our cancer portfolio with several large diagnostic and liquid biopsy companies, with the goal of signing multiple licensing agreements this year, including milestone payments in addition to ongoing revenue.
"Volition's nucleosome assays can be run on existing automated chemiluminescence platforms worldwide and do not need new hardware. Our commercial strategy is to leverage this base to make Nu.Q® Cancer testing accessible to patients as widely as possible on existing platforms through licensing and partnership arrangements."
About the study
The study investigated a novel immunoassay method for the measurement of small amounts of cell-free nucleosomes in the blood of 229 cancer patients (including 70 early-stage cancer patients) and 150 healthy subjects. Findings published in the paper currently undergoing peer review and accessible on medRxiv, demonstrated the Nu.Q® Cancer test detected common fatal cancer diseases, including cancers of the lung, breast, prostate, colon and liver (overall AUC=
Dr Jake Micallef, Chief Scientific Officer at Volition, said:
"This is a breakthrough based on 15 years of development work by our scientific team at Volition. Presently, cancer is often diagnosed symptomatically at a late stage when it has spread to other parts of the body, is difficult to treat and can be deadly. Early detection of cancer at stage I or II is therefore a long-term goal in clinical practice. The accuracy, low-cost and routine nature of the Nu.Q® Cancer test means it may be useful, alongside current cancer screening methods, for detecting cancer before symptoms become apparent, helping to reduce unnecessary invasive biopsies, facilitating early treatment and improving patient outcomes."
Professor Léa Payen, Department of Biochemistry and Molecular Biology, Hospices Civils de
"Circulating nucleosome levels show great promise as clinically useful biomarkers in oncology. We are working with Volition to advance the use of nucleosome measurements not only in early cancer detection but also in the management of cancer patients, particularly in the detection of Minimal Residual Disease for assessment of treatment efficacy."
1.Data on file, Volition TAM model.
About Volition
Volition is a multi-national epigenetics company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential not only to prolong the life of patients but also to improve their quality of life.
Volition's research and development activities are centered in
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620
Investor Relations
Jeremy Feffer, LifeSci Advisors, jfeffer@lifesciadvisors.com +1-212-915-2568
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the timing, completion, success and delivery of data from clinical studies, the timing of publications, , the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and Volition's success in securing licensing and/or distribution agreements with third parties for its products. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this press release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™, Capture-PCR™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.
View original content:https://www.prnewswire.com/news-releases/volitions-nuq-cancer-diagnostics-test-aims-to-disrupt-the-multi-billion-dollar-liquid-biopsy-industry-302407833.html
SOURCE VolitionRx Limited
FAQ
What cancers can VolitionRx's Nu.Q® Cancer test detect?
How does VNRX plan to commercialize the Nu.Q® Cancer test?
What is the market size for VNRX's liquid biopsy technology?
What are the key advantages of VNRX's Nu.Q® Cancer test platform?
